Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · March 25, 2021

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin in Primary Cardiovascular Prevention

Diabetes Care

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
Diabetes Care 2021 Mar 02;[EPub Ahead of Print], A Cahn, I Raz, LA Leiter, O Mosenzon, SA Murphy, EL Goodrich, I Yanuv, A Rozenberg, DL Bhatt, DK McGuire, JPH Wilding, IAM Gause-Nilsson, AM Langkilde, MS Sabatine, SD Wiviott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading